



Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/763,309
Filing Date	January 23, 2004
First Named Inventor	Kaesemeyer
Group Art Unit	1614 1623
Examiner Name	Not yet assigned

Sheet 1 of 2 Attorney Docket Number 126625.801

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
<i>lrc</i>	AAA	5,595,970		Garfield et al.	01-21-1997	
	AAB	5,665,077		Rosen et al.	09-09-1997	
	AAC	5,482,925		Hutsell	01-09-1996	
	AAD	5,405,919		Keefer et al.	04-11-1995	
	AAE	5,543,430		Kaesemeyer	08-06-1996	
	AAF	5,767,160		Kaesemeyer	06-16-1998	
	AAG	4,857,522		DiPietro et al.	08-15-1989	
	AAH	5,190,970		Pan et al.	03-02-1993	
	AAI	5,461,039		Tschollar et al.	10-24-1995	
	AAJ	5,316,765		Folkers et al.	05-31-1994	
	AAK	4,920,098		Cotter et al.	04-24-1990	
	AAL	5,106,836		Clemens et al.	04-21-1992	
	AAM	5,171,217		March et al.	12-15-1992	
	AAN	5,278,189		Rath et al.	01-11-1994	
	AAO	5,428,070		Cooke et al.	06-27-1995	
	AAP	5,650,418		Rath et al.	07-22-1997	
	AAQ	5,852,058		Cooke et al.	12-22-1998	
	AAR	5,861,168		Cooke et al.	01-19-1999	
<i>lrc</i>	AAS	5,891,459		Cooke et al.	04-06-1999	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
<i>lrc</i>	ABL	WO	92/11895		Boston Scientific Corp.	07-23-1992		
	ABM	WO	95/05866		Cortrak Medical, Inc.	03-12-1995		
	ABN	WO	96/08286		Local Med, Inc.	03-21-1996		
	ABO	WO	84/02131		Sandoz AG	06-07-1984		
<i>lrc</i>	ABP	EP	0546796	A1	Ajinomoto Co., Inc.	06-16-1993		

Examiner Signature	L. E. Crane	Date Considered	12/13/2006
--------------------	-------------	-----------------	------------

*reference not available at this time, will provide in a supplemental filing

<p>Substitute for form 1449/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>			Complete if Known	
			Application Number	10/763,309
			Filing Date	January 23, 2004
			First Named Inventor	Kaesemeyer
			Group Art Unit	1614 1623
Examiner Name	Not yet assigned			
Sheet	2	of 2	Attorney Docket Number	126625.801
OTHER ART (Including Author, Title, Date, Permanent Pages, Etc.)				
Examiner's Initials	Cite No.			
<i>MC</i>	ACR	Ignarro, Louis J, PhD, 1991, Pharmacology of Endothelium-Derived Nitric Oxide and Nitrovasodilators, The Western Journal of Medicine, pp. 51-62.		
<i>MC</i>	ACS	Stewart, D.D., 1888, Remarkable Tolerance to Nitroglycerin, Philadelphia Polyclinic, 172-5.		
<i>MC</i>	ACT	Freelisch et al., Biochem. and Biophys. Res. Comm. 1991: 180, No 1: 286-293.		
<i>MC</i>	ACU	Sunderkotter, et al., J. Leukoc. Biol. 1994 Mar, 55(3) L 410-22.		
INC.	ACV	Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton PA)		
<i>JHC</i>	ACW	Chester, Adrian H. et al., Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. The Lancet, Vol. 336 (4870), Westmoorout, 10/13/1990, 7 pages.		
<i>JHC</i>	ACX	Wolf, Yelinda G. et al., Nitroglycerin decreases medial smooth muscle cell proliferation after arterial balloon injury, Journal of Vascular Surgery, March 1995, p. 499-503. Vol. 21, Issue # 3, only Abstract supplied.		
<i>JHC</i>	ACY	Harrison, David G., Endothelial Modulation of Vascular Tone: Relevance to Coronary Angioplasty and Restenosis, JACC, Vol. 17, No. 6, May 1991, p. 71B-76B.		
<i>JHC</i>	ACZ	Feldmani, M. et al., Microfabricated Device for Intravascular Delivery, JACC, February 1998, p. 351A, Abs. # 870-6.		
<i>JHC</i>	BCR	Ra, K. et al., JPET, 1982, 221: 525-531, only Abstract Supplied.		
MSG.	BCS	Draper, N.J. et al., Contrasting Effect of NO Synthase Inhibition on LV Function During Early and Late Reoxygenation, Heart, p. 187.*		
<i>JHC</i>	BCT	Niebauer, et al., Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis, Division of Cardiovascular Medicine, Stanford University, 1999 American Heart Association, Inc., 1830-1835, 14, 100.		
Examiner Signature	L. E. Crane <i>L. E. Crane</i>		Date Considered	12/13/2006

*reference not available at this time, will provide in a supplemental filing

INC. - Incomplete bibliography: need publisher, location, date, pages supplied, etc.

MSG. Not considered because no copy supplied. (missing).



Substitution Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known	
Application Number	10/763,309
Filing Date	January 23, 2004
First Named Inventor	Kaesemeyer
Group Art Unit	1614 — 1623
Examiner Name	Dwayne G. Jones

Attorney Docket Number

126625.801

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
<i>JKC</i>	AA	4,259,314		Lowey	03-31-1981	
<i>JKC</i>	AB	5,451,409		Rencher et al.	09-19-1995	
<i>JKC</i>	AC	4,369,172		Schor et al.	01-18-1983	
<i>JKC</i>	AD	4,389,393		Schor et al.	06-21-1983	
<i>JKC</i>	AE	4,983,396		Bodor et al.	01-08-1991	
<i>JKC</i>	AF	5,543,430		Kaesemeyer	08-06-1996	
<i>JKC</i>	AG	5,767,160		Kaesemeyer	06-16-1998	
<i>JKC</i>	AH	5,968,983		Kaesemeyer	10-19-1999	
<i>JKC</i>	AI	4,857,522		DiPietro et al.	08-15-1989	
<i>JKC</i>	AJ	5,190,970		Pen et al.	03-02-1993	
<i>JKC</i>	AK	5,461,930		Tschellar et al.	10-24-1995	
<i>JKC</i>	AL	5,316,766		Folkers et al.	05-31-1994	
<i>JKC</i>	AM	6,147,109		Liao et al.	11-14-2000	
<i>JKC</i>	AN	6,239,172		Kaesemeyer	05-29-2001	

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
<i>JKC</i>	BA	WO	9844893		Kaesemeyer	10-15-1998		
<i>JKC</i>	BB	WO	0056403		Brigham & Women's Hospital	09-28-2000		

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
<i>JKC</i>	CA	ROBINSON, Sustained Action Dosage Forms in The Theory and Practice of Industrial Pharmacy 2 nd ed., Lachman et al eds., Ch. 14:439-465, 1976						
<i>JKC</i>	CB	IGNARRO, Pharmacology of Endothelium-Derived Nitric Oxide and Nitrovasodilators, 1991, The Western Journal of Medicine, pp. 51-62						
<i>JKC</i>	CC	FEELISCH et al., Biotransformation of Organic Nitrates to Nitric Oxide by Vascular Smooth Muscle and Endothelial Cells, 1991, Biochem. and Biophys. Res. Comm. 180(1):286-293						
<i>JKC</i>	CD	SUNDERKOTTER et al., Macrophages and angiogenesis, 1994, J. Leukoc. Biol. Mar. 55(3):410-422						
INC	CE	Remington's Pharmaceutical Sciences, 1990, 18 th ed., Gennaro ed., Mack Publishing, Easton, PA (TOC)						
INC	CF	Handbook of Pharmaceutical Excipients, Boylan et al. eds., 1986 (TOC)						
INC	CG	Pharmaceutical Dosage Forms: Tablets, 2 nd ed., Lieberman et al. eds., 1990 (TOC)						

Examiner Signature

L. E. Crane

Date Considered

12/13/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

dup - Duplicate citation: see PTO-1449 #1 for original cite.

INC. - Incomplete bibliography: need publisher, location, date, pages supplied, etc

PT: #255601 v1 (SH81011.DOC)